Take, for example, the pharmaceutical company Amgen. By looking at the effects of Dreyer’s thick-bone mutation, they reasoned, they could find a treatment for osteoporosis. People with sclerosteosis, the condition that results from high bone density, are missing a protein that inhibits how thick bones can grow. So the researchers tried hundreds of antibodies over several years to develop a drug that blocks the protein in osteoporosis patients to help their bones grow thicker, reversing the effects of the disease. They tested the drug on mice that went into space (where bones usually lose density) and it worked well--the mice that were given the drug gained bone mineral density while those who were not lost it. Now they are in the final stages of human trials that seem similarly promising.